Poland’s Polpharma asks US court to grant Swiss arbitration in TS case

Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

14 July 2026 An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

Pharma

What’s at stake in Australia’s biggest pharma patent appeal in years?

1 July 2026 Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.

More features

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin

Poland’s Polpharma asks US court to grant Swiss arbitration in TS case

More on this story

Editor's picks

Editor's picks

More features